6918.TW A Plus Biotechnology Co., Ltd.
- Market cap
- TWD 2.45B
- P/E
- 13.3x
- P/B
- 2.04x
- ROE
- 17.2%
- Dividend yield
- 4.98%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6918.TW undervalued?
Graham number6918.TW trades 10.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
A Plus Biotechnology Co., Ltd. fundamental analysis
No fundamental analysis for A Plus Biotechnology Co., Ltd. yet.
A Plus Biotechnology Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About A Plus Biotechnology Co., Ltd.
A Plus Biotechnology Co., Ltd. engages in the manufacturing and wholesale of medical devices in Taiwan, China, and internationally. The company provides bone graft materials and other medical devices, as well as technical support services. It also offers products for chest, shoulder, spine, elbow, wrist and hand, pelvic and hip, knee, foot and ankle, osteotomy, pediatric and ESF, and biologics. In addition, the company provides trauma products, including internal fixation pl…
Full company profileA Plus Biotechnology Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
A Plus Biotechnology Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 542M | 615M | 675M | 770M | 836M | 925M |
| Gross Profit | 346M | 372M | 461M | 535M | 573M | 613M |
| Operating Income | 46.1M | 66.6M | 168M | 182M | 209M | 228M |
| EBITDA | - | 95.6M | 32.1M | 216M | 246M | 286M |
| Net Income | 32.9M | 45.7M | -11.3M | 151M | 169M | 207M |
| EPS | 1.08 | 1.50 | -0.37 | 4.96 | 4.96 | 6.07 |
| Balance Sheet | ||||||
| Total Assets | 1.21B | 1.17B | 1.07B | 1.18B | 1.55B | 1.55B |
| Total Liabilities | 362M | 297M | 243M | 258M | 284M | 346M |
| Shareholders' Equity | 844M | 878M | 828M | 919M | 1.26B | 1.20B |
| Cash & Short-term Investments | 305M | 238M | 319M | 361M | 604M | 476M |
| Cash Flow | ||||||
| Operating Cash Flow | 53.0M | 60.6M | 159M | 161M | 159M | 204M |
| Capital Expenditure | 225M | 36.8M | 9.81M | 9.14M | 13.6M | 265M |
| Free Cash Flow | -172M | 23.9M | 149M | 152M | 145M | -61.6M |
| Ratios | ||||||
| ROE | 3.9% | 5.2% | -1.4% | 16.4% | 13.4% | 17.2% |
| ROA | 2.7% | 3.9% | -1.1% | 12.8% | 10.9% | 13.4% |
| Net Profit Margin | 6.1% | 7.4% | -1.7% | 19.6% | 20.3% | 22.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
A Plus Biotechnology Co., Ltd. dividends
- Dividend yield
- 4.98%
- Forward dividend
- 5.00 TWD
- Payout ratio
- 72.0%
- Ex-dividend date
- Mar 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 122M | 3.57 | 72.0% |
| 2024 | TWD 81.5M | 2.67 | 53.9% |
| 2023 | TWD 21.1M | 0.70 | - |
| 2022 | TWD 15.2M | 0.50 | 33.3% |
| 2021 | TWD 14.3M | 0.47 | 43.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns A Plus Biotechnology Co., Ltd.
- Insiders 39.70%
- Institutions 2.05%
- Public & others 58.25%
- Shares outstanding 34.1M
- Free float 21.2M
A Plus Biotechnology Co., Ltd. company profile
- Company name
- A Plus Biotechnology Co., Ltd.
- Ticker
- 6918.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- December
- Address
- No.21, Qiaohe Rd, New Taipei City, Taiwan, 235
- Phone
- 886 2 2249 9222
- Website
- aplusbio.com
About A Plus Biotechnology Co., Ltd.
A Plus Biotechnology Co., Ltd. engages in the manufacturing and wholesale of medical devices in Taiwan, China, and internationally. The company provides bone graft materials and other medical devices, as well as technical support services. It also offers products for chest, shoulder, spine, elbow, wrist and hand, pelvic and hip, knee, foot and ankle, osteotomy, pediatric and ESF, and biologics. In addition, the company provides trauma products, including internal fixation plates, screws, pins, intramedullary nails, cables, and external fixators; correction products, such as knee preservation systems, hallux valgus correction systems, additive manufacturing surgical guides; and distributed products comprising artificial bone substitutes, cell therapy, hemostatic products, breathable casts, powered surgical instruments, carbon fiber bone plates, etc. A Plus Biotechnology Co., Ltd. was incorporated in 2009 and is based in New Taipei City, Taiwan.
A Plus Biotechnology Co., Ltd. management
2- Xiang-Wei LuoGM & Director
- Pei Jun KeAccounting Supervisor